Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial

Authors

Renata Ferrarotto
Priyadharsini Nagarajan
Jacob M Maronge
Jason M Johnson
David I Rosenthal
Jeffrey N Myers
Neil D Gross

Publication Date

9-1-2023

Journal

JAMA Otolaryngology – Head & Neck Surgery

DOI

10.1001/jamaoto.2023.1729

PMID

37535378

PMCID

PMC10401391

PubMedCentral® Full Text Version

Post-print

Abstract

This secondary analysis of a phase 2 clinical trial examines long-term survival for resectable cutaneous squamous cell carcinoma of the head and neck according to pathologic response.

Keywords

Humans, Carcinoma, Squamous Cell, Skin Neoplasms, Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Head and Neck Neoplasms, Treatment Outcome

Published Open-Access

yes

Recommended Citation

Ferrarotto, Renata; Nagarajan, Priyadharsini; Maronge, Jacob M; et al., "Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial" (2023). Faculty, Staff and Student Publications. 3388.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3388